Sagimet Biosciences Inc. Deferred Costs, Current
Sagimet Biosciences Inc. (SGMT) had Deferred Costs, Current of $434.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2026-08-11
- 2026-06-30: Deferred Costs, Current $434.00K.
- 2026-03-31: Deferred Costs, Current $402.00K.
- 2025-12-31: Deferred Costs, Current $282.00K.
- 2025-09-30: Deferred Costs, Current $247.00K.
| Period end | Deferred Costs, Current |
|---|---|
| 2026-06-30 | $434.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $402.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $282.00K 10-Q · filed 2026-08-11 |
| 2025-09-30 | $247.00K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $620.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $625.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $306.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $306.00K 10-Q · filed 2024-11-14 |
| 2023-12-31 | $323.00K 10-K · filed 2025-03-12 |
| 2023-06-30 | $2.64M 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |